Avastin Trial Enrollment To Resume With Heightened Cardiac Monitoring
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche/Genentech's AVANT study of bevacizumab showed no increase in cardiac adverse events, according to an independent data safety monitoring board.